Covid-19 vaccine, virtually assuring a second option for protecting against the deadly virus for a pandemic ravaged country.The committee voted 20-0 with one abstention that the benefits of the Covid-19 vaccine outweigh its risks in people aged 18 and older, one week after the same panel backed a similar vaccine from American giant Pfizer and its German partner BioNTech SE, leading to an FDA emergency use authorization (EUA) a day later, reports news agency Reuters.Also Read | Covid curve slumping across IndiaThe US Food and Drug Administration is expected to grant the EUA as early as late Thursday or Friday, providing another ray of hope to a nation that has lost over 300,000 people to the killer virus, including a one-day high of 3,580.